Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Shanta Chawla, MD
Spectrum Pharmaceuticals, Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clearview Cancer Center
Huntsville, Alabama, United States
- Pacific Cancer Medical Center, Inc.
Anaheim, California, United States
- Marin Cancer Care, Inc
Greenbrae, California, United States
- Alliance Research Centers
Laguna Hills, California, United States
- Pacificshores Medical Group
Long Beach, California, United States
- Valley Medical Oncology Consultants
Pleasanton, California, United States
- Innovative Clinical Research Institute
Whittier, California, United States
- Ampm Research Clinic
Miami Gardens, Florida, United States
- Fl Cancer Research Institute
Plantation, Florida, United States
- Bond Clinic, P.A.
Winter Haven, Florida, United States
- Triple Army Medical Cente
Honolulu, Hawaii, United States
- Franciscan St. Francis Health
Indianapolis, Indiana, United States
- the University of Kansas Cancer Center and Medical Pavilion
Westwood, Kansas, United States
- Hattiesburg Clinic Hematology Oncology
Hattiesburg, Mississippi, United States
- Washington University
St Louis, Missouri, United States
- St. Vincent Frontier Cancer Center
Billings, Montana, United States
- North Shore Hematology Oncology Associates
East Setauket, New York, United States
- Hudson Valley Hematology Oncology Associates
Poughkeepsie, New York, United States
- White Plain Hospital
White Plains, New York, United States
- Waverly Hematology Oncology
Cary, North Carolina, United States
- Aultman Hospital
Canton, Ohio, United States
- Ohio State University
Columbus, Ohio, United States
- Oklahoma Cancer Specialists & Research Institute, Llc
Tulsa, Oklahoma, United States
- Magee Womens Hospital of Upmc
Pittsburgh, Pennsylvania, United States
- Charleston Cancer Center
Charleston, South Carolina, United States
- Carolina Blood and Cancer Care Associates Pa
Rock Hill, South Carolina, United States
- Oncology Consultants, P.A.
Houston, Texas, United States
- Sammc - Hem/onc Clinic
Houston, Texas, United States
- Texas Oncology-Mcallen
McAllen, Texas, United States
- the University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
- Scott & White Memorial Hospital
Temple, Texas, United States
- Providence Regional Cancer System
Lacey, Washington, United States
- Medical Oncology Associates, Ps
Spokane, Washington, United States
- Northwest Medical Specialties, Pllc
Tacoma, Washington, United States
- West Virginia University
Morgantown, West Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Feb 2016
- Primary completion
- 11 Mar 2020
- Completion
- 11 Mar 2020
- Last update posted
- 11 Mar 2022
- Registered enrollment
- 67
- Registry id
- NCT02659514
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.